Subscribe to the CrunchBase Daily
for the latest on Fundings, Acquisitions, and Startup Events
Board of Directors
Onyx Pharmaceuticals is a biopharmaceutical company committed to improving the lives of people with cancer. Their lead product is NexavarÂ® (sorafenib), a novel, oral multiple kinase inhibitor that targets proteins involved in both tumor cell proliferation and angiogenesis.
Above: Onyx Pharmaceuticals
Amgen Said to Be Near Deal to Buy Onyx for $10.5 Billion (dealbook.nytimes.com) 
Onyx strikes $851M deal to buy Proteolix (fiercebiotech.com)